The efficacy of home telemonitoring versus conventional follow-up: a randomised controlled trial among teenagers with inflammatory bowel disease.

The efficacy of home telemonitoring versus conventional follow-up: a randomised controlled trial among teenagers with inflammatory bowel disease. J Crohns Colitis. 2017 Dec 08;: Authors: Heida A, Dijkstra A, Muller Kobold A, Rossen J, Kindermann A, Kokke F, de Meij T, Norbruis O, Weersma R, Wessels M, Hummel T, Escher H, van Wering H, Hendriks D, Mearin L, Groen H, Verkade H, van Rheenen P Abstract Background and aims: Conventional follow-up of teenagers with inflammatory bowel diseases (IBD) is done during scheduled outpatient visits regardless of how well the patient…

Read More

Editorial: thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype-the perils of ageing. Authors’ reply.

Editorial: thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype-the perils of ageing. Authors’ reply. Aliment Pharmacol Ther. 2018 Jan;47(1):130-131 Authors: Broekman MMTJ, Wanten GJ, de Jong DJ PMID: 29226420 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29226420?dopt=Abstract

Read More

The long-term effects of faecal microbiota transplantation for gastrointestinal symptoms and general health in patients with recurrent Clostridium difficile infection.

The long-term effects of faecal microbiota transplantation for gastrointestinal symptoms and general health in patients with recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2017 Dec 11;: Authors: Jalanka J, Hillamaa A, Satokari R, Mattila E, Anttila VJ, Arkkila P Abstract BACKGROUND: Faecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridium difficile infection. In short-term the treatment has been shown to be safe, however, there are no large, long-term follow-up studies looking into the potential adverse effects. AIM: To analyse the long-term effect of FMT treatment in patients with…

Read More

Vedolizumab-associated pancreatitis in paediatric ulcerative colitis – functional selectivity of the α4β7integrin and MAdCAM-1 pathway?

Vedolizumab-associated pancreatitis in paediatric ulcerative colitis – functional selectivity of the α4β7integrin and MAdCAM-1 pathway? J Crohns Colitis. 2017 Dec 08;: Authors: Lopez RN, Gupta N, Lemberg DA PMID: 29228226 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29228226?dopt=Abstract

Read More

Anti-infliximab antibody concentrations can guide on treatment intensification in patients with Crohn’s disease who lose clinical response.

Anti-infliximab antibody concentrations can guide on treatment intensification in patients with Crohn’s disease who lose clinical response. Aliment Pharmacol Ther. 2017 Dec 11;: Authors: Dreesen E, Van Stappen T, Ballet V, Peeters M, Compernolle G, Tops S, Van Steen K, Van Assche G, Ferrante M, Vermeire S, Gils A Abstract BACKGROUND: The presence of antibodies towards infliximab (ATI) is associated with lower infliximab (IFX) trough concentrations and loss of response. IFX treatment intensification is effective for restoring response in most, but not all patients with Crohn’s disease (CD). AIM: To…

Read More

Letter: biologics treatment in Crohn’s disease and risk of bowel resection-what about the patients who stop anti-TNF therapy?

Letter: biologics treatment in Crohn’s disease and risk of bowel resection-what about the patients who stop anti-TNF therapy? Aliment Pharmacol Ther. 2018 Jan;47(1):146-147 Authors: Ribaldone DG, Saracco G, Astegiano M, Pellicano R PMID: 29226397 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29226397?dopt=Abstract

Read More

Letter: biologics treatment in Crohn’s disease and risk of bowel resection-what about the patients who stop anti-TNF therapy? Authors’ reply.

Letter: biologics treatment in Crohn’s disease and risk of bowel resection-what about the patients who stop anti-TNF therapy? Authors’ reply. Aliment Pharmacol Ther. 2018 Jan;47(1):147-148 Authors: Eberhardson M, Söderling JK, Olén O PMID: 29226402 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29226402?dopt=Abstract

Read More
<< Go Back